Superior Planning, LLC’s Alnylam Pharmaceuticals ALNY Stock Holding History

Superior Planning, LLC’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$36.8K	Buy	+149	New	+$37.9K	0.02%	466

Other funds holding ALNY

Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 20.64% 1-Year Est. Return

American Century Companies Kansas City, Missouri $229B AUM 33.35% 1-Year Est. Return

Superior Planning, LLC's ALNY Position: Q3 2026 in Review

Superior Planning, LLC opened a new position in Alnylam Pharmaceuticals (ALNY) in Q3 2026: 149 shares worth $36.8K. The stake represents 0.02% of the portfolio and ranks #466 among its holdings.

492 funds tracked by Wall St. Rank hold ALNY as of Q3 2026.

Superior Planning, LLC held 149 shares of Alnylam Pharmaceuticals worth $36.8K as of Q3 2026.
Alnylam Pharmaceuticals was a new Superior Planning, LLC position in Q3 2026.
Alnylam Pharmaceuticals made up 0.02% of Superior Planning, LLC's portfolio in Q3 2026, its #466 holding.
492 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2026.

Based on Superior Planning, LLC's 13F filing for Q3 2026, filed 12 Nov 2026.